The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, bought 8,400 equity shares of the company through the open market on September 26, 2025. His stake increased from 6,85,300 shares (30.03%) to 6,93,700 shares (30.39%), a rise of 0.37 percentage points. The total equity share capital of the company remains unchanged at 22,82,400 shares. The disclosure was filed under Regulation 29(2) of the SEBI Takeover Regulations.
A small open-market purchase by the promoter signals continued confidence in the company, but the size of the acquisition is too small to materially affect shareholding or trigger any regulatory threshold. No significant price impact expected.